Immunomedics (IMMU) – Litigation
-
Immunomedics (IMMU) Announces $125M Private Placement of Convertible Preferred Stock; Outlines Strategic Steps to Drive Stockholder Value; CEO to Step Down
-
Seattle Genetics (SGEN) Terminates License Agreement with Immunomedics (IMMU) for Sacituzumab Govitecan (IMMU-132)
-
-
-
-
-
-
-
-
-
-
Back to IMMU Stock Lookup